Citrulline Supplementation for High Blood Pressure in Postmenopausal Women

Recruiting in Palo Alto (17 mi)

Overseen by Arturo Figueroa

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Texas Tech University

Trial Summary

What is the purpose of this trial?

The objective of this project is to elucidate the effect of L-Citrulline (L-CIT) supplementation on vascular function at rest and during rhythmic handgrip exercise and functional sympatholysis via lower-body negative pressure in postmenopausal women with elevated blood pressure and hypertension.

Research Team

Arturo Figueroa

Principal Investigator

Texas Tech University

Eligibility Criteria

This trial is for postmenopausal women aged 50-70 with a BMI of 25-39.9, who exercise less than two hours per week and have high blood pressure (120-150 mmHg). They must not be on certain medications or have had recent changes in their hypertension treatment, nor should they have cardiovascular diseases, diabetes, musculoskeletal disorders, cancer, or habits like smoking and heavy drinking.

Inclusion Criteria

Your blood pressure when you are not active is between 120 and 150 mmHg.

Your body mass index is between 25 and 39.9.

I have not had a menstrual period for at least one year.

Exclusion Criteria

Your blood pressure is higher than 150 mmHg when the heart is pumping.

You drink more than 7 alcoholic drinks per week.

You are currently involved in a weight loss or exercise program.

Treatment Details

Interventions

• L-Citrulline (Other)
• Placebo (Other)

Trial Overview The study tests if L-Citrulline supplements can improve blood vessel function at rest and during handgrip exercises in postmenopausal women with high blood pressure. Participants will either receive the supplement or a placebo to compare effects.

Participant Groups

Group I: L-Citrulline Experimental Treatment 1 Intervention

L-Citrulline: 6 grams/day divided in 2 equal doses

Group II: Placebo Placebo Group 1 Intervention

Microcrystalline cellulose: 8 capsules/day divided into 2 equal doses

Who Is Running the Clinical Trial?

Texas Tech University

Lead Sponsor

Trials

89

Recruited

10,300+

Dr. Lance McMahon

Texas Tech University

Chief Executive Officer since 2023

PhD in Pharmacodynamics from the University of Florida

Dr. Phillip S. Sizer Jr.

Texas Tech University

Chief Medical Officer since 2023

MD from Yale University